A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS EFFICACY AND SAFETY OF TWO DOSES OF CRIZANLIZUMAB VERSUS PLACEBO, WITH OR WITHOUT HYDROXYUREA/ HYDROXYCARBAMIDE THERAPY, IN ADOLESCENT AND ADULT SICKLE CELL DISEASE PATIENTS WITH VASO-OCCLUSIVE CRISES (STAND)
- Registry ID
- CSEG101A2301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2021-03-15
- Last update
- 2019-05-29
Conditions
Related clinical trials
- A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER,
DOSE-FINDING, EFFICACY, AND SAFETY STUDY OF TEBAPIVAT IN PARTICIPANTS WITH
SICKLE CELL DISEASE
- A PHASE 2A, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE MULTIPLE DOSING REGIMENS OF SUBCUTANEOUS ALXN1820 IN ADULT PATIENTS WITH SICKLE CELL DISEASE
- EARLY HLA MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE: A SICKLE TRANSPLANT ALLIANCE FOR RESEARCH (STAR) TRIAL
- A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MITAPIVAT IN SUBJECTS WITH SICKLE CELL DISEASE
- THROMBOPROPHYLAXIS IN SICKLE CELL DISEASE WITH CENTRAL VENOUS CATHETERS (THIS): A PILOT STUDY
- "A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A SINGLE DOSE OF AUTOLOGOUS CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS GENE-EDITED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS (EDIT-301) IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE"
View on source registry